Analytical Data
-
Gene name
CYP3A7
- Application
-
Alternative Names
CYP3A7；Cytochrome P450 3A7
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P24462
-
Expression Region
1-503aa
-
AA Sequence
MDLIPNLAVETWLLLAVSLILLYLYGTRTHGLFKKLGIPGPTPLPFLGNALSFRKGYWTFDMECYKKYRKVWGIYDCQQPMLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKNAISIAEDEEWKRIRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKHVFGAYSMDVITSTSFGVSIDSLNNPQDPFVENTKKLLRFNPLDPFVLSIKVFPFLTPILEALNITVFPRKVISFLTKSVKQIKEGRLKETQKHRVDFLQLMIDSQNSKDSETHKALSDLELMAQSIIFIFAGYETTSSVLSFIIYELATHPDVQQKVQKEIDTVLPNKAPPTYDTVLQLEYLDMVVNETLRLFPVAMRLERVCKKDVEINGMFIPKGVVVMIPSYVLHHDPKYWTEPEKFLPERFSKKNKDNIDPYIYTPFGSGPRNCIGMRFALVNMKLALVRVLQNFSFKPCKETQIPLKLRFGGLLLTEKPIVLKAESRDETVSGA
-
Molecular Weight
64.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CYP3A7 is a member of the cytochrome P450 family of enzymes, primarily expressed in the fetal liver and responsible for the metabolism of a variety of endogenous and exogenous compounds. Its expression in adults is significantly lower compared to other CYP3A genes, such as CYP3A4, which is essential for drug metabolism. Recent studies have uncovered that CYP3A7 can metabolize certain medications and hormones, suggesting its potential influence on pharmacokinetics and drug interactions. Additionally, CYP3A7 demonstrates unique substrate specificity and genetic variability among populations, raising interest in its role in personalized medicine. Researchers have been focusing on the recombinant expression of CYP3A7 to facilitate comprehensive studies on its enzymatic functions and metabolic pathways. By producing and studying recombinant CYP3A7, scientists aim to elucidate its specific roles in drug metabolism and to assess its clinical significance. Understanding CYP3A7 can enhance our knowledge of fetal exposure to pharmacological agents, improving the safety and efficacy of drug therapies during pregnancy. Moreover, insights gained from CYP3A7 research could inform dosing strategies and risk assessments in populations with specific genetic backgrounds. Overall, the investigation of CYP3A7 recombinant protein serves as a vital step towards integrating pharmacogenomics into clinical practice, ultimately contributing to more effective and safer therapeutic interventions.
